Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

GRCEBearishCorporate Developmentsnews

High materiality8/10

Grace Therapeutics Faces FDA Setback but Plans to Resubmit GTx-104 NDA

Apr 23, 2026, 1:15 PM EDT3 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The CRL indicates significant regulatory hurdles, which typically lead to price declines until resolved. For instance, similar cases have historically resulted in negative price movements upon CRL announcements.

AI summary

What happened, with direct paths to the underlying reporting

Grace Therapeutics received a Complete Response Letter from the FDA regarding its GTx-104 application for treating aSAH, citing concerns about chemistry, manufacturing, and non-clinical data. The company is confident that they can address these issues, which could lead to a pivotal approval, marking a significant advancement in aSAH treatment after decades.

FDA issued Complete Response Letter for GRCE's GTx-104 NDA.
Issues cited relate to Chemistry, Manufacturing, and Control, and non-clinical data.
Company plans to address issues and resubmit application.
Approval could be first innovation in aSAH treatment in 40 years.
STRIVE-ON trial showed favorable outcomes for GTx-104 compared to oral nimodipine.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Grace Therapeutics Faces FDA Setback but Plans to Resubmit GTx-104 NDA

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study